LLY ELI LILLY & Co

NYSE lilly.com


$ 826.00 $ 1.31 (0.16 %)    

Monday, 27-Oct-2025 17:08:15 EDT
QQQ $ 629.00 $ 3.46 (0.55 %)
DIA $ 475.89 $ 0.53 (0.11 %)
SPY $ 685.72 $ 2.43 (0.36 %)
TLT $ 91.85 $ 0.46 (0.5 %)
GLD $ 366.23 $ -3.96 (-1.07 %)
$ 825.45
$ 825.00
$ 825.80 x 2
$ 827.00 x 1
$ 811.48 - $ 826.42
$ 622.41 - $ 931.66
2,211,150
na
742.74B
$ 0.59
$ 53.82
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-19-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 04-30-2024 03-31-2024 10-Q
7 02-21-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 04-27-2023 03-31-2023 10-Q
11 02-22-2023 12-31-2022 10-K
12 11-01-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 04-29-2022 03-31-2022 10-Q
15 02-23-2022 12-31-2021 10-K
16 10-27-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 04-30-2021 03-31-2021 10-Q
19 02-17-2021 12-31-2020 10-K
20 10-28-2020 09-30-2020 10-Q
21 07-31-2020 06-30-2020 10-Q
22 05-01-2020 03-31-2020 10-Q
23 02-19-2020 12-31-2019 10-K
24 10-25-2019 09-30-2019 10-Q
25 08-02-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 02-19-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 07-25-2018 06-30-2018 10-Q
30 04-27-2018 03-31-2018 10-Q
31 02-20-2018 12-31-2017 10-K
32 10-27-2017 09-30-2017 10-Q
33 07-28-2017 06-30-2017 10-Q
34 05-01-2017 03-31-2017 10-Q
35 02-21-2017 12-31-2016 10-K
36 10-28-2016 09-30-2016 10-Q
37 07-28-2016 06-30-2016 10-Q
38 04-29-2016 03-31-2016 10-Q
39 02-19-2016 12-31-2015 10-K
40 10-30-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 eli-lillys-omvoh-shows-major-improvement-in-ulcerative-colitis-symptoms-by-week-12-study-finds

New data from Eli Lilly and Company (NYSE:LLY) showed Omvoh-treated patients with moderately to severely active ulcerative coli...

 avidity-shareholders-win-big-as-novartis-moves-fast-on-12-billion-deal

Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash.

 eli-lillys-new-ebglyss-results-back-flexible-treatment-options-for-atopic-dermatitis

Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Ol...

 eli-lilly-bets-big-on-eye-gene-therapy-that-could-end-repeat-injections

Lilly (LLY) to acquire Adverum Biotechnologies (ADVM) for $12.47 per share, with potential CVR payments tied to future milestones.

 mounjaro-maker-eli-lilly-jumps-in-quality-despite-trump-fueled-price-cut-fears

Eli Lilly jumps to top 10% in quality rankings, showing strong fundamentals even as Trump pushes for weight loss drug price cut...

Core News & Articles

This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areat...

 eli-lillys-ebglyss-shows-comparable-efficacy-with-q8w-dosing-in-phase-3-adjoin-extension-trial-supporting-less-frequent-dosing-option

New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) wi...

 weight-loss-drugs-are-quietly-exploding-employer-health-insurance-costs-there-is-a-quiet-alarm-bell-going-off

Employer-sponsored health insurance costs rise for third year, with average family premiums at $27,000 in 2025. Drug costs and ...

 no-place-is-risk-free-until-the-world-is-polio-free-bill-gates-urges-global-action-to-close-deadly-immunity-gaps

Polio cases drop 99.9%, but funding shortfall could undo progress. Last mile hardest as virus exploits immunity gaps.

 benzinga-bulls-and-bears-stellantis-papa-johns-oklo--and-trade-tensions-shake-chip-stocks

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our t...

 trumps-weight-loss-drug-push-may-put-these-etfs-on-a-diet

Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.

 trump-induced-volatility-aside-novo-trades-cheap-while-patents-protect-its-profits-until-2032

Novo Nordisk offers cheap stock with strong moat and long-term growth tailwinds. Trump's drug price cut suggestion caused s...

 eli-lilly-shares-are-trading-lower-friday-whats-going-on

Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss ...

 novo-vs-lilly-vs-pfizer-who-wins-if-trump-slashes-the-price-of-weight-loss-drugs

Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential imp...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION